ABSTRACT.
The Plasminogen activators convert inactive proenzyme plasminogen to the active enzyme, plasmin (22) . They have been classified as two immunologically distinct groups ; urokinase-type and tissue-type plasminogen activators (t-PA) (21) . Urokinase, an isolate from human urine that consists of two polypeptide chains linked by one disulfide bond (molecular weight 50,000), has been used clinically in thrombolytic therapy. Thrombolysis by urokinase is associated with systemic plasminogen activation, the degradation of fibrinogen and the coagulation proteins in circulating blood (5, 25) . In contrast, the t-PA produced by a human melanoma cell line has been shown to be a more specific and effective thrombolytic agent than urokinase because of its high affinity for fibrin and its thrombus-localized stimulation of plasminogen activator activity without the activation of systemic plasminogen or the degradation of plasma proteins (9, 16, 20) .
The plasminogen activator produced by human kidney cells in culture has been reported to be identical with urinary urokinase (2). But Bernik et al. (3) have suggested the existence of a plasminogen activator as a proenzyme, whose activity could be enhanced by trypsin. Furthermore, Striver et al. (24) recently purified the plasminogen activator released as an inactive proenzyme from murine cells transformed by Sarcoma virus.
We also have succeeded in purifying a noble type of plasminogen activator secreted from cultured human kidney cells and obtained the following results (KASAI, S., H. ARIMURA, M. NISHIDA and T. SUYAMA. Submitted for publication). The plasminogen activator was inactive and had a single-chain structure and a molecular weight of 50,000. It was converted to the active two-chain form with the same molecular weight by catalytic amounts of plasmin. Cleavage of the plasminogen activator induced conformational changes which followed the generation of plasminogen activator activity. The plasminogen activator activity generated was quenched completely by anti-urokinase IgG, but not by anti-t-PA Ig. These results are evidence that the plasminogen activator is an inactive proenzyme form of human urokinase. Therefore, the plasminogen activator was termed single-chain pro-urokinase. Results of our investigation of the thrombolytic properties of this single-chain pro-urokinase suggest that it is a more specific and effective thrombolytic agent than urokinase and that its properties are similar to those of t-PA. 
RESULTS
Binding of the single-chain pro-urokinase to fibrin clots. The fibrin-binding activities of the single-chain pro-urokinase and urokinase were compared. The affinity of the single-chain pro-urokinase for fibrin was much higher than that of urokinase (Fig. 1) .
Comparisons of fiibrinolytic and fibrinogenolytic activities. The relative fibrinolytic and fibrinogenolytic properties of the single-chain pro-urokinase and urokinase were compared. First, the effects of the single-chain pro-urokinase (or urokinase) on the degradation of fibrin were studied. The lysis of 125I-labeled plasma clots by urokinase increased as the amount of urokinase increased, but urokinase failed to 1 yze plasma clots completely even at 1,500 IU/ml during the incubation period (Fig.  2) . When fibrinolysis by single-chain pro-urokinase (500 IU/ml) took place, the fibrinolytic process followed a sigmoidal curve, complete 1ysis taking place within 4 h. The in vitro thrombolytic system demonstrated that the single-chain pro- two-chain form depends on the presence of plasma clots. The conversion is triggered by the plasmin generated during coagulation that is bound to fibrin via a specific binding site (7) .
DISCUSSION
To determine the thrombolytic properties of the single-chain pro-urokinase obtained from tissue-cultured human kidney cells, we compared the relative fibrinbinding, and the fibrinolytic and fibrinogenolytic properties of this single-chain pro-urokinase with those of urokinase.
The affinity of the single-chain pro-urokinase for fibrin was much higher than that of urokinase (Fig. 1) . Plasminogen (23) and t-PA (18) have kringle domains that participate in their affinity for fibrin. Urokinase recently has been shown to have a kringle domain that has an extensive homology with plasminogen and t-PA kringles (6) . In confirmation of previous reports (1, 4) we found a low affinity of urokinase for fibrin in the study reported here. We previously showed that a conformational change takes place during the conversion of single-chain pro-urokinase to the active two-chain form by plasmin (KASAI, S., H. ARIMURA, M. NISHIDA and T. SUYAMA. Submitted for publication). These results indicate that the kringle structure of the single-chain pro-urokinase takes a functionally active form which is changed to the less active form during the conversion of single-chain pro-urokinase to the two-chain form. Our in vitro thrombolytic studies disclosed that single-chain pro-urokinase is approximately three times more potent in fibrinolysis than urokinase (Fig. 2) . Another interesting observation was that single-chain pro-urokinase does not degrade the fibrinogen in the plasma at a concentration, at which a complete plasma clot lysis takes place, but that urokinase degrades the fibrinogen in the plasma extensively (Fig. 3) . We infer that single-chain pro-urokinase differs in its thrombolysis mechanism from that of urokinase. Because urokinase acts directly on the plasminogen present in the plasma as well as on the plasminogen adsorbed on the thrombus and converts the inactive proenzyme plasminogen to the active enzyme plasmin, both the degradation of the thrombus (Fig. 2) and the degradation of the fibrinogen in the plasma (Fig. 3) are caused by urokinase nonspecifically (5, 25) .
Because single-chain pro-urokinase is stable in plasma (Fig. 4) and has no plasminogen activator activity in it (data not shown), but has a high affinity for fibrin, it is localized on the thrombus without degradation of the fibrinogen in the plasma. There it combines with fibrin and subsequently is converted to the two-chain form (Fig. 5) on the thrombus by catalytic amounts of plasmin generated during coagulation. It appears that on the thrombus the active two-chain form then converts the plasminogen bound to the fibrin molecule to plasmin, thus effectively degrading the thrombus without degrading the fibrinogen in the plasma. Furthermore, the fact that the degree of clot lysis (Fig. 2) paralleled the conversion of single-chain prourokinase (Fig. 5 ) supports this explanation of thrombolysis by single-chain prourokinase.
Our studies provide evidence that single-chain pro-urokinase is a more specific and effective thrombolytic agent than urokinase and that its thrombolytic properties are similar to those of t-PA (9, 19, 20) . Single-chain pro-urokinase with its inactive proenzyme form and its high affinity for fibrin might be better than urokinase for use in thrombolytic therapy.
